/PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat.
/PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat.
STOCKHOLM, Dec. 10, 2021 /PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological
Investegate announcements from Immunicum AB, Immunicum to Present Data Update on Phase II ADVANCE II at Annual American Society of Hematology Meeting (ASH)
Press Release November 4, 2021 Immunicum to Present Data Update on Phase II ADVANCE II at Annual American Society of Hematology Meeting (ASH) Immunicum AB (publ; IMMU.ST), a biopharmaceutical